American Association for Cancer Research
10780432ccr180372-sup-195985_3_supp_5108549_pgfznv.xlsx (15.59 kB)

Supplemental Table 1 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

Download (15.59 kB)
posted on 2023-03-31, 20:33 authored by Lillian M. Guenther, Neekesh V. Dharia, Linda Ross, Amy Conway, Amanda L. Robichaud, Jerrel L. Catlett, Caroline S. Wechsler, Elizabeth S. Frank, Amy Goodale, Alanna J. Church, Yuen-Yi Tseng, Rajarshi Guha, Crystal G. McKnight, Katherine A. Janeway, Jesse S. Boehm, Jaume Mora, Mindy I. Davis, Gabriela Alexe, Federica Piccioni, Kimberly Stegmaier

Related to Figure 1


Dana-Farber Cancer Institute/Novartis Drug Discovery Program grant

Brian MacIsaac Sarcoma Foundation

Cookies for Kids Cancer




Novel targeted therapeutics have transformed the care of subsets of patients with cancer. In pediatric malignancies, however, with simple tumor genomes and infrequent targetable mutations, there have been few new FDA-approved targeted drugs. The cyclin-dependent kinase (CDK)4/6 pathway recently emerged as a dependency in Ewing sarcoma. Given the heightened efficacy of this class with targeted drug combinations in other cancers, as well as the propensity of resistance to emerge with single agents, we aimed to identify genes mediating resistance to CDK4/6 inhibitors and biologically relevant combinations for use with CDK4/6 inhibitors in Ewing. We performed a genome-scale open reading frame (ORF) screen in 2 Ewing cell lines sensitive to CDK4/6 inhibitors to identify genes conferring resistance. Concurrently, we established resistance to a CDK4/6 inhibitor in a Ewing cell line. The ORF screen revealed IGF1R as a gene whose overexpression promoted drug escape. We also found elevated levels of phospho-IGF1R in our resistant Ewing cell line, supporting the relevance of IGF1R signaling to acquired resistance. In a small-molecule screen, an IGF1R inhibitor scored as synergistic with CDK4/6 inhibitor treatment. The combination of CDK4/6 inhibitors and IGF1R inhibitors was synergistic in vitro and active in mouse models. Mechanistically, this combination more profoundly repressed cell cycle and PI3K/mTOR signaling than either single drug perturbation. Taken together, these results suggest that IGF1R inhibitors activation is an escape mechanism to CDK4/6 inhibitors in Ewing sarcoma and that dual targeting of CDK4/6 inhibitors and IGF1R inhibitors provides a candidate synergistic combination for clinical application in this disease.